Treatment of locally advanced prostate cancer: Is chemotherapy the next step?

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3664-3675

  Oh, William K ^a   Kantoff, Philip W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; DIETHYLSTILBESTROL; ESTRAMUSTINE; FLUTAMIDE; GONADORELIN; KETOCONAZOLE; MEGESTROL ACETATE; MITOXANTRONE; PACLITAXEL; PLATINUM; VINBLASTINE;

ADVANCED CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW;

EID: 0032745009     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3664     Document Type: Review

References (71)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Jones GW, Mettlin C, Murphy GP, et al: Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990. J Am Coll Surg 180:545-554, 1995
3. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948-954, 1993
4. Mordkin RM, Hayes WS, Kuettel MR, et al: Management of locally advanced prostate cancer. Oncology 10:1289, 1299-1300, 1996
5. Perrapato SD, Carothers GG, Maatman TJ, et al: Comparing clinical staging plus transrectal ultrasound with surgical-pathologic staging of prostate cancer. Urology 33:103-105, 1989
6. D'Amico AV, Schnall M, Whittington R, et al: Endorectal coil magnetic resonance imaging identities locally advanced prostate cancer in select patients with clinically localized disease. Urology 51:449-454, 1998
7. Polascik TJ, Manyak MJ, Haseman MK, et al: Comparison of clinical staging algorithms and 111 In-capromab pendetide immunoscintigraphy to predict lymph node involvement in high-risk prostrate cancer patients. Cancer 85:1586-1592, 1999
8. Grignon DJ, Caplan R, Sarkar FH, et al: p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst 89:158-165, 1997
9. Morgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 41:113-120, 1993
10. Freeman JA, Esrig D, Grossfeld GD, et al: Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. J Urol 154:474-478, 1995
11. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:3582-3593, 1993
12. Ahmann FR: A review of the neoadjuvant and adjuvant treatment of prostate cancer, in Salmon SE (ed): Adjuvant Therapy of Cancer VIII. Philadelphia, PA, Lippincott-Raven Publishers, 1997, pp 217-225
13. Johansson JE, Holmberg L, Johansson S, et al: Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA 277:467-471, 1997
14. Gerber GS: Conservative approach to the management of prostate cancer: A critical review. Eur Urol 26:271-275, 1994
15. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980, 1998
16. Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248, 1994
17. Schmidt JD, Mettlin CJ, Natarajan N, et al: Trends in patterns of care for prostatic cancer, 1974-1983: Results of surveys by the American College of Surgeons. J Urol 136:416-421, 1986
18. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
19. Bosch RJ, Kurth KH, Schroeder FH: Surgical treatment of locally advanced (T3) prostatic carcinoma: Early results. J Urol 138:816-822, 1987
20. Gerber GS, Thisted RA, Chodak GW, et al: Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 32:385-390, 1997
21. Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349:906-910, 1997
22. Hanks GE, Krall JM, Hanlon AL, et al: Patterns of Care and RTOG studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 28:39-45, 1994
23. Bagshaw MA, Cox RS, Ray GR: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 47-60, 1988
24. Zagars GK, von Eschenbach AC, Johnson DE, et al: Stage C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam radiation. Cancer 60:1489-1499, 1987
25. Perez CA, Hanks GE, Leibel SA, et al: Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3): Review of management with external beam radiation therapy. Cancer 72:3156-3173, 1993
26. Fuks Z, Leibel SA, Wallner KE, et al: The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1251 implantation. Int J Radiat Oncol Biol Phys 21:537-547, 1991
27. Zietman AL, Shipley WU: Progress in the management of T3-4 adenocarcinoma of the prostate. Eur J Cancer 33:555-559, 1997
28. Kuban DA, el-Mahdi AM, Schellhammer P: The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys 24:409-414, 1992
29. Scardino PT, Frankel JM, Wheeler TM, et al: The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol 135:510-516, 1986
30. Leibel SA, Heimann R, Kutcher GJ, et al: Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: Preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys 28:55-65, 1994
31. Corn BW, Hanks GE, Schultheiss TE, et al: Conformai treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys 32:325-330, 1995
32. Russell KJ, Caplan RJ, Laramore GE, et al: Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: Results of a randomized prospective trial. Int J Radiat Oncol Biol Phys 28:47-54, 1994
33. Miller RJ Jr, Cohen JK, Merlotti LA: Percutaneous transperineal cryosurgical ablation of the prostate for the primary treatment of clinical stage C adenocarcinoma of the prostate. Urology 44:170-174, 1994
34. Proceedings of the 1st International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. Boston, MA, March 29-30, 1996. Urology 49:1-118; quiz 121-123, 1997
35. Van Poppel H, De Ridder D, Elgamal AA, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial - The Belgian Uro-Oncological Study Group. J Urol 154:429-434, 1995
36. Soloway MS, Hachiya T, Civantos F, et al: Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer. Urology 43:52-56, 1994
37. Aus G, Abrahamsson PA, Ahlgren G, et al: Hormonal treatment before radical prostatectomy: A 3-year follow-up. J Urol 159:2013-2016, 1998
38. Bonney WW, Schned AR, Timberlake DS: Neoadjuvant androgen ablation for localized prostatic cancer: Pathology methods, surgical end points and meta-analysis of randomized trials. J Urol 160:1754-1760, 1998
39. Green N, Bodner H, Broth E, et al: Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys 10:971-976, 1984
40. Zagars GK, Pollack A, von Eschenbach AC: Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80:764-775, 1997
41. Pilepich MV, Buzydlowski JW, John MJ, et al: Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: Outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys 32:175-180, 1995
42. Pilepich MV, Krall JM, al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995
43. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
44. Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 165-170, 1988
45. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 79:235-246, 1997
46. Fleischmann JD, Catalona WJ: Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol 134:498-500, 1985
47. Fellows GJ, Clark PB, Beynon LL, et al: Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment: A Medical Research Council Study - Urological Cancer Working Party-Subgroup on Prostatic Cancer. Br J Urol 70:304-309, 1992
48. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985
49. Oh WK, Kantotf P: Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 160:1220-1229, 1998
50. Schmidt JD, Gibbons RP, Murphy GP, et al: Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 29:425-433, 1996
51. Khil MS, Kim JH, Bricker LJ, et al: Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci Am 3:289-296, 1997
52. Kelly K, Gaudin P, Slovin S, et al: Paclitaxcl (T), estramustine (E), and carboplatin (C) in patients with advanced prostate cancer. J Urol 161:177, 1999 (abstr 683)
53. Perez EA, Foo ML, Fulmer JT: Management of locally advanced breast cancer. Oncology 11:9-17, 1997
54. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949-955, 1997
55. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
56. Turrisi A, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
57. Kuban DA, el-Mahdi AM, Schellhammer PF: Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 75:2373-2382, 1995
58. Zincke H, Utz DC, Taylor WF: Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: Role of adjuvant treatment for residual cancer and in disease progression. J Urol 135:1199-1205, 1986
59. van den Ouden D, Davidson PJ, Hop W, et al: Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 151:646-651, 1994
60. Lerner SE, Blute ML, Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: Outcome and contemporary morbidity. J Urol 154:1447-1452, 1995
61. Oesterling JE FZ, Lee C, et al: Cancers of the genitourinary system, in DeVita VT HS, Rosenberg SA (ed): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, Inc. 1997, p 1356
62. Bagshaw MA, Kaplan ID, Cox RC: Prostate cancer: Radiation therapy for localized disease. Cancer 71:939-952, 1993
63. Zagars GK, Pollack A, von Eschenbach AC: Prostate cancer and radiation therapy: The message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33:23-35, 1995
64. Kennedy TJ, Sonneland AM, Marlett MM, et al: Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 147:891-893, 1992
65. Andros EA, Danesghari F, Crawford ED: Neoadjuvant hormonal therapy in stage C adenocarcinorna of the prostate. Clin Invest Med 16:510-515, 1993
66. Oesterling JE, Andrews PE, Suman VJ, et al: Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149:779-782, 1993
67. Macfarlane MT, Abi-Aad A, Stein A, et al: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 150:132-134, 1993
68. Narayan P, Lowe BA, Carroll PR, et al: Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate. Br J Urol 73:544-548, 1994
69. Aprikian AG, Fair WR, Reuter VE, et al: Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 74:630-636, 1994
70. Cher ML, Shinohara K, Breslin S, et al: High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol 75:771-777, 1995
71. Lee F, Siders DB, McHug TA, et al: Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Anticancer Res 17:1507-1510, 1997